CD274 and neoplasm: In the Keynote 224 trial, the response to pembrolizumab seemed to be linked to PD-L1 expression quantified with expression in both tumor cells and nontumor cells lymphocytes and macrophages for CPS (ORR 32% versus 20%; p = 0.021), but not PD-L1 expression on tumor cells alone, and TPS (ORR 43% versus 22%; p = 0.088) [80].